Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06253130 · ClinicalTrials.gov registry record · Phase 1

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Eikon Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
156
Enrollment target
20
Study locations

NCT06253130 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 156 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06253130, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Eikon Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
156 participants
Enrollment target
20
Study locations

Study Summary

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG IMP1734

Study Locations (20)

California

  • Hoag Health Center Irvine - Irvine
  • University California Irvine - Irvine
  • Sharp Memorial Hospital - San Diego
  • University of California San Francisco (UCSF) - San Francisco

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor
  • Karmanos Cancer Institute - Detroit
  • Henry Ford Health - Detroit

Florida

  • Advent Health Research Institute - Celebration
  • Sylvester Comprehensive Cancer Center - Miami

Arizona

  • The University of Arizona Cancer Center - Tucson

Arkansas

  • University of Arkansas Winthrop P. Rockefeller Cancer Institute - Little Rock

Colorado

  • Sarah Cannon Research Institute Health One - Denver

Connecticut

  • Smilow Cancer Hospital at Yale New Haven - New Haven

Minnesota

  • University of Minnesota-Clinical Research Unit - Minneapolis

Trial Details

FieldValue
Enrollment Target 156 participants
Start Date 2023-12-11
Est. Completion 2027-12-01
Phase Phase 1

Sponsor

Eikon Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06253130

The ClinicalTrials.gov registry entry for NCT06253130 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMP1734 is the first listed.

NCT06253130 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Michigan, Florida.

Frequently Asked Questions

What is clinical trial NCT06253130 about?

NCT06253130 is a clinical study titled "A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors". This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

What is the current status of trial NCT06253130?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2023-12-11. Estimated completion is 2027-12-01.

What conditions does trial NCT06253130 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06253130?

The interventions under investigation include: IMP1734 (DRUG).

Who is sponsoring clinical trial NCT06253130?

This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06253130 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.